Research Article

Activation of Penile Proadipogenic Peroxisome Proliferator-Activated Receptor γ with an Estrogen: Interaction with Estrogen Receptor Alpha during Postnatal Development

Mahmoud M. Mansour, 1 Hari O. Goyal, 2 Tim D. Braden, 1 John C. Dennis, 1 Dean D. Schwartz, 1 Robert L. Judd, 1 Frank F. Bartol, 3 Elaine S. Coleman, 1 and Edward E. Morrison 1

1 Departments of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
2 Department of Biomedical Sciences, Tuskegee University, Tuskegee, AL 36088, USA
3 Cellular and Molecular Biosciences Program, Department of Animal Sciences, Auburn University, Auburn, AL 36849, USA

Correspondence should be addressed to Mahmoud M. Mansour, mansoma@auburn.edu

Received 23 April 2008; Accepted 14 July 2008

Recommended by Carolyn Komar

Exposure to the estrogen receptor alpha (ERα) ligand diethylstilbestrol (DES) between neonatal days 2 to 12 induces penile adipogenesis and adult infertility in rats. The objective of this study was to investigate the in vivo interaction between DES-activated ERα and the proadipogenic transcription factor peroxisome proliferator-activated receptor gamma (PPARγ). Transcripts for PPARα, β, and γ and γ1a splice variant were detected in Sprague-Dawley normal rat penis with PPARγ predominating. In addition, PPARγ1b and PPARγ2 were newly induced by DES. The PPARγ transcripts were significantly upregulated with DES and reduced by antiestrogen ICI 182, 780. At the cellular level, PPARγ protein was detected in urethral transitional epithelium and stromal, endothelial, neuronal, and smooth muscular cells. Treatment with DES activated ERα and induced adipocyte differentiation in corpus cavernosum penis. Those adipocytes exhibited strong nuclear PPARγ expression. These results suggest a biological overlap between PPARγ and ERα and highlight a mechanism for endocrine disruption.

Copyright © 2008 Mahmoud M. Mansour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Endocrine disruption, originally limited to steroid receptor signaling, now extends to include other members of the 48 reported nuclear receptor superfamily [1]. Both peroxisome proliferator-activated receptor gamma (PPARγ) and estrogen receptor alpha (ERα) are targets for endocrine disrupting chemicals [2–4]. Recently, Goyal et al. showed that neonatal exposure of rats to the estrogenic endocrine disruptor diethylstilbestrol (DES) induced adipogenesis in penile corpus cavernosum by activation of ERα [5–8]. In this model of DES-ERα activation, DES exposure at a dose of 0.1 to 0.12 mg/kg bw/day, on alternate days, from postnatal days 2 to 12, resulted in infertility in 100% of the treated male rats. Loss of fertility was associated with abnormal accumulation of fat cells in the corpus cavernosum penis, and the associated loss of cavernous spaces apparent as early as postnatal day 18 (reviewed in [9]). It remains unknown, however, whether this penile ERα-induced adipogenesis is mediated by activation of a constitutively expressed or DES-induced PPARγ.

Both ERα and PPARγ pathways are implicated in fat regulation. First, recent findings suggest that PPARγ and ERα pathways involve shared coactivators that promote differentiation of preadipocytes into mature fat cells. For example, constitutive coactivator of PPARγ (CCPG) is described as a bona fide coactivator that cross-reacts with ERα independent of its ligand and contains four LXXLL motifs that are characteristic of nuclear receptor coactivators [10]. Second, studies have shown that forced expression of PPARγ2 or PPARγ1 can trigger the differentiation of fibroblasts to adipocytes resulting in the activation of adipocyte-specific genes and lipid accumulation [11].
The PPAR family consists of three isoforms that include PPARα (NR1C1), PPARβ (also known as PPARδ, NR1C2, FAAR, or NUC-1), and PPARγ (NR1C3) [12–14]. A nuclear receptor, PPARγ, is known to play a central role in fat metabolism and adipocyte differentiation [15, 16]. The PPARγ is present in two key isoforms, PPARγ1 and PPARγ2. The two isoforms stem from alternate promoters [17]. Compared to PPARγ1, PPARγ2 has an additional 30 amino acids at the N-terminal end and is distinctively expressed in adipose tissue, where it plays a key role in adipogenesis [18]. These nonsteroidal receptors (i.e., do not mediate effects of steroids) form part of a class I nuclear hormone receptor superfamily [19] and function as ligand-activated transcription factors [20–22].

Each of the three PPAR isoforms is constitutively expressed in certain reproductive and nonreproductive rat tissues [23, 24], but their temporal and cell-specific expression in penile tissue, with the exception of a limited demonstration of PPARγ in penile corporal smooth muscle cells [25], has not been shown. Further, no specific link is known between neonatal activation of ERα and penile PPARγ. This is important given the expanded definition of the term endocrine disruptors to include activation of metabolic sensors such as PPARs. A number of findings suggest involvement of PPARs in endocrine disruption either through direct receptor activation or indirectly through cross-talk with other nuclear receptors. First, in vitro studies demonstrated that PPARγ and ERα (the iconic receptor involved in endocrine disruption) are implicated in cross-talk [26–28]. Second, some endocrine disruptor chemicals, such as monohydric acid phthalate (MEHP), a primary metabolite of diethylhexyl phthalate (DEHP), mediate their toxic effect by PPARγ activation [29, 30]. Third, several nonbiological xenobiotics compounds can activate PPARγ. For example, activation of PPARγ with synthetic PPARγ activators, such as antidiabetic drugs thiazolidinediones (TZDs), improve insulin sensitivity but they undesirably increase adipocyte differentiation and white adipose tissue mass [31–33]. Consistent with this adipogenic effect, reduced PPARγ level, as in mice with heterozygous (PPARγ+) and PPARγ−/− deficiency, is associated with reduced white adipose tissue mass [34].

Findings related to interaction between ERα and PPARγ in the aforementioned DES-penile rat model will illuminate a potential molecular mechanism by which estrogen exposure at critical period of development perturbs reproductive tissues. Therefore, we hypothesize that DES-induced penile adipogenesis is associated with ERα-mediated activation of PPARγ. Objectives of this study were to (1) determine the basal expression of PPARs (α, β, and γ) in rat penis and (2) evaluate the neonatal modulatory effect of ERα-activator DES on penile PPARγ as a marker of undesirable adipogenesis.

2. MATERIALS AND METHODS

2.1. Animals and treatments

This DES study was performed in collaboration with Dr. Hari Goyal at Tuskegee University using male pups from pregnant female Sprague-Dawley (SD) rats (Harlan Sprague-Dawley, Indianapolis, Ind, USA). All animal procedures were approved by Institutional Animal Care and Use Committee at Tuskegee University. In all experiments, rats were maintained using standard housing conditions including constant temperature of 22°C, ad libitum water and feeding, and 12:12 hours light dark cycle. Two experiments were conducted. In experiment 1, three groups of male pups (n = 5 per group, all were littermates) received subcutaneous injections of 25 μL of olive oil (control), oil containing DES (0.1 mg/kg, Sigma-Aldrich, St. Louis, Miss, USA), or DES plus ICI 182, 780 (16.6 mg/kg, ICI; Tocris Bioscience, Ellisville, Miss, USA) daily on postnatal day 2 to 6. Rats in experiment 1 were sacrificed at 28 day of age. ICI 182, 780 is a high-affinity estrogen receptor antagonist (IC50 = 0.29 nM) and is also considered a high-affinity ligand for the membrane estrogen receptor GPR30 (Tocris Bioscience). In experiment 2, two groups of male pups (n = 4 per group) received DES (1 mg/kg) or olive oil (control) every other day for 6 days starting at postnatal day 2. Penile tissues were collected from rats sacrificed at 120 days of age (adulthood). Small sections of the penile shaft tissue from each rat in experiment 1 and 2 were fixed overnight in 4% paraformaldehyde for IHC or fat staining, and the remainder of the shaft tissue was frozen in liquid nitrogen and stored at −80°C for RNA extraction and PCR analysis. The doses used for end-point evaluation at 28 and 120 days post-treatment were based on previous publications from our group that showed DES prenatal exposure (between postnatal days 2 to 12) at a dose range of 0.1 to 0.12 mg/kg/day, or higher (1 mg/kg/day) result in similar abnormal penile development and adipogenesis [5, 8].

2.2. Total RNA isolation

Total RNA was isolated from the body of the penis using TRIzol reagent (Invitrogen-Life Technologies Inc., Carlsbad, Calif, USA), according to the manufacturer’s protocol. RNA concentrations were estimated at 260 nm and the ratio of 260/280 was determined using UV spectrophotometry (DU640, Beckman Coulter Fullerton, Calif, USA). The integrity of each RNA sample, indicated by the presence of intact 28S and 18S ribosomal RNA, was verified by denaturing agarose gel electrophoresis. RNA samples were treated with DNase (Ambion Inc.) to remove possible genomic DNA contamination. Samples with 260/280 ratio of ≥1.8 were used.

2.3. Conventional end-point and real-time PCR

Expression of mRNA for PPAR (α, β, and γ) isoforms was initially determined by conventional end-point RT-PCR with primers designed using primer quest software and synthesized by Integrated DNA Technology (IDT Inc, Coralville, Iowa, USA) from previously published rat sequences (see Table 1). Subsequently, semiquantitative RT-PCR for coamplification of PPARs and S-15 (known as Rig; small subunit ribosomal protein used as a house keeping gene) was performed to determine the relative expression levels of
Table 1: PCR primer sets, sequence, product size (bp), nucleotide (nt) location, and GenBank accession numbers for rat PPARs used in this study. Note that a common antisense oligoprimer (sequence in bold) was used for PPARγ1α, PPARγ1β, and PPARγ2.

| Product/accession# | Sense primer | Antisense primer | Product size (bp) | nt location |
|--------------------|--------------|------------------|------------------|-------------|
| PPARα NM013196     | 5-TTG TGA CTG GTC AAG CTC AGG ACA-3 | 5-TCG TAC GCC AGT TTT AGC GGA ATA-3 | 492            | 296–787     |
| PPARβ U40064       | 5-TAA CGC ACC CTT CAT CAT CCA CGA-3 | 5-TCG TAC GCC AGT TTT AGC GGA ATA-3 | 390            | 873–1262    |
| PPARγ NM013124     | 5-TCT CCA GCA TTT CTG CTC CAC ACT-3 | 5-ATA CAA ATG CTT TGC CAG GGC TCG-3 | 533            | 257–789     |
| PPARγ1a AF246458   | 5-CTG ACG AGG TCT CTC TC G GCT - G3 | 5-AGC AAG GCA CTT CT G AA ACC GA-3 | 658            | 21–679      |
| PPARγ1b AF246457   | 5-CAG CGG TAA ATT CAT CTT AAC T-3 | 5-AGC AAG GCA CTT CT G AA ACC GA-3 | 618            | 21–639      |
| PPARγ2 AB019561    | 5-GAG CAT GGT GCC TTC GCT GA-3 | 5-AGC AAG GCA CTT CT G AA ACC GA-3 | 563            | 37–600      |
| PPARγ/ERα NM012689 | (primers for real-time PCR were obtained from Superarray Inc) | (Sequence are not disclosed by the Company) | 190/179 | [PPARγ/ERα] respectively |
| Gapdh DQ403053     | 5-ATG ATT CTA CCC ACG GCA AG-3 | 5-CTG GAA GAT GGT GAT G CTT T-3 | 89             | 71–159      |
| BC087743 BC059110  | 5-GAG CAT GGT GCC TTC GCT GA-3 | 5-AGC AAG GCA CTT CT G AA ACC GA-3 | 86–649        | 50–125       |
| Rig/S15 (Ambion)   | 5-TTC CGC AAG TTC ACC TAC C-3 | 5-CGG GGC CGG CCA TGC T TTA CG-3 | 361            | 74–433      |

PPAR isotypes. Verification of accurate PCR products was confirmed by determination of the expected size of PCR bands and by sequence analysis of generated amplicons at Auburn University sequencing facility. The resulting sequences for the three PPAR isotypes were matched with previously published rat sequences in GenBank (accession numbers NM013196, U40064, and NM013124 for PPARα, PPARβ, and PPARγ, respectively) using Chromas 2.31 software (Technelysium Pty Ltd, Tewantin Qld 4565, Australia). PPAR splice variants or subtypes were identified using specific primers designed for rat PPARγ1α and PPARγ1β synthesized by IDT Inc. (Table 1). Liver and white adipose tissues from adult Sprague-Dawley rats in experiment 2 were used as positive controls for PPARγ1α and PPARγ2. The amplification protocol was as follows: initial cycle for 3 minutes at 95°C, and 30 cycles each at (95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds) followed by a final extension cycle at 72°C for 7 minutes. PCR reactions were performed on a Robocycler (Stratagene Inc, La Jolla, Calif, USA) and products were analyzed electrophoretically on 2% (w/v) agarose gels. The intensity of the PCR bands was determined using Fluor-S multi-imaging analysis system (Bio-Rad, Hercules, Calif, USA). Level of mRNA for PPARs was normalized to the levels of S-15 housekeeping gene.

Quantitative real-time PCR (Bio-Rad, MyiQ™) for determination of expression levels of PPARγ and ERα mRNA was performed in 25-μL reaction mixture containing 12.5 μL RT² real-time SYBR/Fluorescein Green PCR master mix, 1 μL first strand cDNA, 1 μL RT² validated PCR primer set for PPARγ or ERα (Super Array Bioscience Corporation, Frederick, Md, USA), and 10.5 μL PCR-grade water (Ambion Inc). Samples were run in 96-well PCR plates (Bio-Rad, Hercules, Calif, USA) in duplicates, and the results were normalized to GAPDH (see primer set in Table 1) expression. The amplification protocol was set at 95°C for 15 minutes for one cycle, and 40 cycles each at (95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds) followed by melting curve determination between 55°C and 95°C to ensure detection of a single PCR product. Template RNA from rat white adipose tissue and penis were used for determination of amplification efficiencies for (ERα/PPARγ) targets and GAPDH by generating standard curves. Curves were generated by using serial 10-fold dilutions total RNA.
and plotting the log dilution against C_T (threshold cycle) value obtained for each dilution. The Pearson’s correlation coefficient (r) value for each generated standard curve was ≥0.98, and the calculated amplification efficiency was between 98.5 to 99%.

2.4. Immunohistochemistry (IHC)

Immunolocalization of PPARγ in penile tissue was performed using mouse anti-PPARγ IgG1 monoclonal antibody (sc7273, Santa Cruz Biotechnology Inc, Santa Cruz, Calif, USA) raised against a C-terminus sequence of human and mouse PPARγ (similar to the corresponding rat sequence). The antibody detects PPARγ1, PPARγ2 and, to a lesser extent, PPARα and PPARβ of rat, mouse, and human by IHC using paraplast-embedded tissues. Approximately 5-mm-long penis sections from the middle of the body of the penis were fixed in 4% paraformaldehyde for 48 hours, embedded in Paraplast (Sigma-Aldrich), and cut at 5-μm thickness.

2.5. Fat staining

Histochemical demonstration of fat was performed as previously described [7]. Briefly, tissue sections from penile body, approximately 5-mm-long, were fixed for 24 hours in 4% formaldehyde, followed by en bloc staining of fat for 8 hours with 1% osmium tetroxide dissolved in 2.5% potassium dichromate solution. Specimens were then processed for paraplast embedding and cut at 5-μm thickness. Deparaffinized sections were examined for black staining indicative of fat cells using light microscopy.

2.6. Statistical analyses

Analysis of real-time PCR data for relative gene expression level (fold change of target relative to control) was performed using a modification of the delta delta Ct method (ΔΔ CT) as described previously [36]. Statistical differences between treatment groups were performed using Sigma Stat statistical software (Jandel Scientific, Chicago, Ill, USA). Δ CT for real-time PCR data [37], and intensity values (for semi-quantitative RT-PCR data) were subjected to analyses of variance. Experimental groups with means significantly different (P < .05) from controls were identified using Holm-Sidak and Tukey tests. When data were not distributed normally, or heterogeneity of variance was identified, analyses were performed on transformed or ranked data.

3. RESULTS

3.1. Detection and sequence analysis of PPAR and ERα transcripts in the body of the penis

Primer sets used in this study are shown in Table 1. Transcripts for three PPAR isoforms (α, β, and γ) were detected, albeit at different levels, in penile tissue from normal control adult (120 days) rats (Figure 1, parts A1 and A2). Semi-quantitative RT-PCR analysis of PPARs indicated predominant expression of PPARγ mRNA when compared with PPAR (α and β) isoforms (Figure 1(B)). Sequence analysis and alignment with published sequence data confirmed the identity of all three PPAR isoforms. Treatment with DES induced over three-fold-increase (3.38) in ERα transcripts in 28-day-old rats compared to over two-fold-increase (2.5) in 120-day-old adult rats when each age group was compared with its respective untreated controls (Figure 2). Similarly, DES induced slightly over seven-fold-increase (7.1) in PPARγ transcription level in 28-day-old rats compared with over six-fold-increase (6.8) in 120-day-old adult rats (Figure 3). The upregulation of PPARγ expression by DES in 28-day-old rats was abrogated when rats were cotreated with DES and ICI 182,780 (Figure 4). The differences in the transcriptional level of penile ERα and PPARγ between the DES-treated rat groups (28 versus 120-day-old rats) were not significantly different. Because of the relatively high expression of penile PPARγ in the 28-day-old rats subsequent studies for determination of splice variants and PPARγ protein expression were performed in the 28-day-old rats.

3.2. Detection of PPARγ splice variants and real-time PCR data

In order to determine which PPARγ splice variant is expressed in the body of normal and DES-treated rats, primers (Table 1) were designed to amplify the two known rat PPARγ1a and PPARγ1b splice variants using conventional end-point RT-PCR. Splice variant analyses revealed expression of PPARγ1a in normal 28-day-old rat penis. However, in addition to PPARγ1a, PPARγ1b and PPARγ2 were newly induced by DES treatment (Figure 5).
**Figure 1**: (A1) and (A2) RT-PCR amplification of three PPARs (α, β, and γ) from the body of the penis of three (1, 2, and 3) normal adult (120 days) control rats. (A1) Shows coamplification of PPARs (α, β, and γ (upper bands) and S15 (small ribosomal subunit protein as housekeeping gene, lower bands) in two representative rats (1 and 2). PCR markers were included in lane 1. Expected band sizes for S-15, PPARα, PPARβ, and PPARγ were 361, 492, 390, and 533 bp, respectively. Identities of amplicons were further confirmed by sequence analysis (see Section 2). Note that the ampilicons for PPARβ and S15 in lane 5 and 6 were overlapped (compare run for PPARα, PPARβ, and PPARγ without S15 shown for rat 3 in (A2). In all rats note the predominant expression of PPARγ. 15 μL PCR products were loaded per each lane. (B) Graphic representation of signal intensity for PPARs showing predominant expression of PPARγ. Transcript levels were normalized to the levels of S15 housekeeping gene. To calculate the intensity for PPARβ the mean intensity of S-15 in lanes 2, 3, 8, and 9 in Figure (A1) was subtracted from the combined intensity of PPARβ + S15 in lanes 5 and 6 to obtain the intensity of penile PPARβ for rat 1 and 2, respectively. *P < .05.

**3.3. Immunohistochemistry and fat staining**

Immunohistochemistry results revealed PPARγ protein localization in transitional epithelium of the urethra, and the surrounding corpus spongiosum penis. It is also expressed in stromal, endothelial, neuronal, and smooth muscular cells of the cavernous sinuses located in the corpus cavernosum region of normal 28-day-old rat penis (Figures 6(a) and 6(b)). Treatment with DES induced a strong staining intensity for PPARγ protein in the peripherally located nuclei of newly induced adipocytes (Figure 6(a), Panel (c) with a magnified inset-box view in C2). PPARγ immunostaining was markedly reduced by ICI 182,780 treatment (Figure 6(b)). In unstained penile sections from 28-day-old and adult DES-treated rats, the new adipocytes were seen as empty spaces similar to fat cells and were specifically localized in the corpus cavernosum region of the penis (Figure 7, panels (b) and (d)). In addition, staining with 1% osmium tetroxide confirmed that the empty spaces were cluster of fat cells (stained as black granules in Figure 7, panels (c) and (e)). No fat cells were seen in penile sections from rats treated with DES + ICI (Figure 7, panels (f) and (g)).

**4. DISCUSSION**

This study demonstrated that three PPAR transcripts (α, β, and γ) are constitutively coexpressed in normal rat penis
ing a synergistic interaction between the two receptors.

Associated with a corresponding increase in PPARγ can activate PPARγα perinatal days. Further, upregulation of ERα subtypes when administered at early perinatal days. It established that some ERα synthetic ligands, such as DES, can activate PPARγ subtypes when administered at early perinatal days. Further, upregulation of ERα by DES was associated with a corresponding increase in PPARγ suggesting a synergistic interaction between the two receptors.

![Graph showing PPARγ fold change relative to GAPDH](image)

**Figure 4:** Real-time PCR data showing attenuation of the effect of DES on PPARγ mRNA by ER blocker ICI 182, 780 in 28-day-old rats treated neonatally with either 25 μL of olive oil (CONT-28 d), oil containing DES (DES-28 d; 0.1 mg/kg bw), or DES plus ICI (DES + ICI; 16.6 mg/kg). ICI treatment significantly inhibited DES-induced PPARγ mRNA [DES-28 d versus DES + ICI]. Comparison between control and DES treated rats showed 7.1 fold increase in expression [CONT-28 d versus DES-28 d]. Letter [a] indicates no significant differences between CONT-28 d and DES + ICI. Data (n = 5) are expressed as mean ±SE. *P < .05.

![RT-PCR amplification of PPARγ splice variants](image)

**Figure 5:** RT-PCR amplification of PPARγ (γ, γ1a, γ1b, and γ2) splice variants in the body of the penis (P) of control (lanes, 2–5) and DES-treated (lanes, 7–10) 28-day-old rats. Lanes 12–15 were amplification products from RNA template obtained from rat liver (L) (used as positive control for PPARγ1b). Lanes 16–19 were RNA template from rat white adipose tissue (F) (used as positive control for PPARγ1a and PPARγ2). Note that only PPARγ and PPARγ1a were detected in (P) of normal rats. In contrast, in DES-treated rats enhanced expression of all PPARγ splice variants can be noted. In addition to PPARγ and PPARγ1a expression (seen in normal rats), PPARγ1b and PPARγ2 were induced by DES-treatment. As expected, PPARγ1b and PPARγ2 were strongly expressed in (L) and (F), respectively. S-15 (S, lane 20) is a housekeeping gene amplified from (P) as control for RT-PCR conditions. The expected amplicon sizes for S, PPARγ1a, PPARγ1b, PPARγ2, and PPARγ are 361, 658, 618, 563, and 533 bp, respectively.

![Immunohistochemical staining](image)

**Figure 6:** (a) Representative immunohistochemical staining for PPARγ protein in the body of the penis of 28-day-old DES-treated (A), (B), and (C) and control untreated rats (D), (E), and (F). Note that PPARγ protein is expressed in DES-treated (DES-28 d) and normal rats (CONT-28 d) with increased intensity and fat cells in DES-treated rats (see panel (C)). Note expression in transitional epithelium of the penile urethra (PU) and the surrounding corpus spongiosum (CS) in (A) and (D) and in the endothelium of blood vessels and smooth muscle cells in the dorsal artery (a) and vein (v), and in nerve fibers of the dorsal nerve (n) of the penis (B) and (E). Similar staining intensity can be seen in the endothelium and smooth muscles of the vascular lacunae (VI) in the corpus cavernosum penis (CC) in control normal rats (F). Note one contrasting difference is that the cavernous spaces in DES-treated rats in panel (C) are replaced with fat cells (Fc) that show increased staining intensity in the cell nucleus located at cell periphery. Panels (C2) and (F2) show a closer view of area outlined by insert box. Control sections (minus primary antibody) were in panels (G), (H), and (I). Scale bar = 30 μm. (b) IHC staining for PPARγ protein was significantly reduced by ICI 182, 780 treatment [compare staining in panels (J) and (M) with (L) and (N)]. Panel (P) is a negative control (minus primary antibody). Scale bar 30 μm.
Previous studies that used in situ hybridization to determine the distribution of PPARs in rat tissues, including reproductive organs, showed expression of PPARα and PPARβ in somatic (Sertoli and Leydig) and in germ cells of the testis, but did not address expression of these two receptors in penile tissue [23, 24]. The role of PPARα and PPARβ in the testis, however, remains unknown. Detailed study addressing expression of PPARγ isotypes in penile tissue is also lacking, with the exception of a study that showed limited penile PPARγ expression in corporal smooth muscle cells [25].

In this study, PPARγ and PPARγ1α were detected in normal rat penis. However, DES as ERα activator distinctively induced expression of PPARγ1b and PPARγ2 splice variants that were not present in control untreated penile tissue. The induction of splice variant PPARγ1b is in agreement with previous in vitro studies that demonstrated activation of PPARγ1 by the endocrine disruptor monoethyl-hexylphthalate in C2C12 mouse skeletal muscle cell line [2], and with MCF-7 breast cancer cells stimulated with E2, the natural ERα ligand [38]. Further, the induction of PPARγ2 concurs with increased adipogenesis observed in the corpus cavernosum penis as PPARγ2 is considered a unique marker for mature adipocytes, and its forced induction is associated with terminal differentiation of preadipocytes or fibroblast cells to functional mature adipocytes [11, 22]. The upregulation of PPARγ was abrogated by coadministration of the type-II antiestrogen ICI 182,780, indicating that DES effects were mediated, at least in part, via the estrogen receptor system. It is possible, however, that ICI may have directly repressed activation of PPARγ as ICI was previously shown to inhibit the action of the selective PPARγ agonist BRL 48, 482 in MDA-MB 231 breast cancer cell culture in the absence of ER [38].

One important difference between this study and previous in vitro studies that addressed signal cross-talk between PPARγ and ERα using MCF-7 cells [38–40] is that the activation of ERα by DES in our study is associated with selective induction of PPARγ1b and PPARγ2. This unique effect resulted in generation of de novo adipocytes that provide direct functional proof for PPARγ2 induction. In contrast to our study, activated ERα by E2 lowers both basal and ligand-stimulated PPARγ-mediated gene reporter activity in MCF-7 cancer cell culture [38]. Likewise, activation of PPARγ in MCF-7 cell culture with the natural PPARγ ligand cyclopentenone 15-deoxy-Δ12,14 prostaglandin J2 (15d-PGJ2) inhibited estrogen-responsive elements [40]. Consequently, the MCF-7 cell culture studies suggest that ERα and PPARγ negatively regulate each other. The reason for the difference between our study and the aforementioned in vitro data could be related to differences between in vitro and in vivo milieu or to the deletional mutants used in the in vitro studies compared with the in vivo wild type receptors in our study. Another reason for the disagreement could be due to differences in coactivators and corepressors present in MCF-7 and penile tissue cells or more importantly to differences in the ligands used. One plausible hypothesis, however, for the increased transcriptional activation of PPARγ1b and PPARγ2 by DES-activated ERα is that exposure of rats to DES at a critical neonatal period of days 1 to 12 is uniquely associated with reprogramming of penile stromal or preadipocytes to mature adipocytes [5–8]. In support of this concept, it is known that postnatal days 1 to 5 in rodents coincide with a period for reproductive tract and adipocyte differentiation [41]. Further, data from other laboratories indicated that neonatal exposure of rodents to DES is associated with increased whole body fat at adulthood.

Figure 7: Micrograph sections from penile body of normal rat (a) and rats treated neonatally with DES (b)–(e) or DES + ICI (f)–(g). Panel (a) was from a normal adult rat stained with H and E for demonstration of normal histological structures of the penis (a: dorsal artery; v: dorsal vein; CC: corpus cavernosum; CS: corpus spongiosum; PU: penile urethra; TA: Tunica albuginea). Panels ((b), unstained) and ((c), stained for fat with 1% osmium tetroxide) were from a 28-day-old rat. Panels ((d), unstained) and ((e), stained for fat with 1% osmium tetroxide and presented as a magnified view of CC and CS regions) were from adult rat (120 days) treated neonatally with DES. Note the empty appearing spaces of fat cells in CC regions in unstained sections (panels (b) and (d)). In sections stained with 1% osmium tetroxide (to confirm presence of fat) fat cells appear as black granules, *. Panels ((f), unstained) and ((g), stained with 1% osmium tetroxide) were from a 28-day-old rat treated neonatally with DES + ICI. Note the absence of empty appearing fat cells and lack of fat staining in CC region. Sections from these rats were used for immunolocalization of PPARγ in Figure 6 parts (a) & (b). Scale bars = 30 μm and 200 μm in other panels.
directly activates PPARγ and promotes adipogenesis in cell culture models [2, 3, 55].

ACKNOWLEDGMENT

The authors would like to thank Mrs. Karen G. Wolfe and Barbara Dresher for technical help.

REFERENCES

[1] M. M. Tabb and B. Blumberg, “New modes of action for endocrine-disrupting chemicals,” Molecular Endocrinology, vol. 20, no. 3, pp. 475–482, 2006.
[2] J. N. Feige, L. Gelman, D. Rossi, et al., “The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor γ modulator that promotes adipogenesis,” The Journal of Biological Chemistry, vol. 282, no. 26, pp. 19152–19166, 2007.
[3] C. H. Hurst and D. J. Waxman, “Activation of PPARα and PPARγ by environmental phthalate monoesters,” Toxicological Sciences, vol. 74, no. 2, pp. 297–308, 2003.
[4] D. V. Henley and K. S. Korach, “Endocrine-disrupting chemicals use distinct mechanisms of action to modulate endocrine system function,” Endocrinology, vol. 147, no. 6, pp. S25–S32, 2006.
[5] H. O. Goyal, T. D. Braden, C. S. Williams, et al., “Abnormal morphology of the penis in male rats exposed neonatally to diethylstilbestrol is associated with altered profile of estrogen receptor-α protein, but not of androgen receptor protein: a developmental and immunocytochemical study,” Biology of Reproduction, vol. 70, no. 5, pp. 1504–1517, 2004.
[6] H. O. Goyal, T. D. Braden, C. S. Williams, P. Dalvi, J. W. Williams, and K. K. Srivastava, “Exposure of neonatal male rats to estrogen induces abnormal morphology of the penis and loss of fertility,” Reproductive Toxicology, vol. 18, no. 2, pp. 265–274, 2004.
[7] H. O. Goyal, T. D. Braden, C. S. Williams, P. Dalvi, M. Mansour, and J. W. Williams, “Estrogen-induced abnormal accumulation of fat cells in the rat penis and associated loss of fertility depends upon estrogen exposure during critical period of penile development,” Toxicological Sciences, vol. 87, no. 1, pp. 242–254, 2005.
[8] H. O. Goyal, T. D. Braden, C. S. Williams, P. Dalvi, M. Mansour, and J. W. Williams, “Permanent induction of morphological abnormalities in the penis and penile skeletal muscles in adult rats treated neonatally with diethylstilbestrol or estradiol valerate: a dose-response study,” Journal of Andrology, vol. 26, no. 1, pp. 32–43, 2005.
[9] H. O. Goyal, T. D. Braden, C. S. Williams, and J. W. Williams, “Role of estrogen in induction of penile dysmorphism: a review,” Reproduction, vol. 134, no. 2, pp. 199–208, 2007.
[10] D. Li, Q. Kang, and D.-M. Wang, “Constitutive coactivator of peroxisome proliferator-activated receptor (PPARγ), a novel coactivator of PPARγ that promotes adipogenesis,” Molecular Endocrinology, vol. 21, no. 10, pp. 2320–2333, 2007.
[11] E. Mueller, S. Drori, A. Aiyer, et al., “Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor γ isoforms,” The Journal of Biological Chemistry, vol. 277, no. 44, pp. 41925–41930, 2002.
[12] S. Green, “PPAR: a mediator of peroxisome proliferator action,” Mutation Research, vol. 333, no. 1-2, pp. 101–109, 1995.
[13] I. Issmann and S. Green, “Cloning of novel members of the steroid hormone receptor superfamily,” Journal of Steroid
Biochemistry and Molecular Biology, vol. 40, no. 1–3, pp. 263–269, 1991.

[14] B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999.

[15] A. Chawla, E. J. Schwarz, D. D. Dimaculangan, and M. A. Lazar, “Peroxisome proliferator-activated receptor (PPAR) y: adipose-predominant expression and induction early in adipocyte differentiation,” Endocrinology, vol. 135, no. 2, pp. 798–800, 1994.

[16] P. Tontonoz, S. Singer, B. M. Forman, et al., “Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor y and the retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 1, pp. 237–241, 1997.

[17] Y. Zhu, C. Qi, J. R. Korenberg, et al., “Structural organization of mouse peroxisome proliferator-activated receptor y (mPPARy) gene: alternative promoter use and different splicing yield two mPPARy isoforms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 17, pp. 7921–7925, 1995.

[18] P. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994.

[19] A. Aranda and A. Pascual, “Nuclear hormone receptors and gene expression,” Physiological Reviews, vol. 81, no. 3, pp. 1269–1304, 2001.

[20] I. Isseman, R. A. Prince, J. D. Tugwood, and S. Green, “The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor,” Biochimie, vol. 75, no. 3-4, pp. 251–256, 1993.

[21] S. A. Kliwer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, “Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors,” Nature, vol. 358, no. 6399, pp. 771–774, 1992.

[22] V. Bocher, I. Pineda-Torra, J.-C. Fruchart, and B. Staels, “PPARs: transcription factors controlling lipid and lipoprotein metabolism,” Annals of the New York Academy of Sciences, vol. 967, pp. 7–18, 2002.

[23] O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, β, and γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.

[24] P. Escher, O. Braissant, S. Basu-Modak, L. Michalik, W. Wahli, and B. Desvergne, “Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding,” Endocrinology, vol. 142, no. 10, pp. 4195–4202, 2001.

[25] I. Kovanez, M. G. Ferrini, D. Vernet, G. Nolacco, J. Rajfer, and N. E. Gonzalez-Cadavid, “Pioglitazone prevents corporal veno-occlusive dysfunction in a rat model of type 2 diabetes mellitus,” BJU International, vol. 98, no. 1, pp. 116–124, 2006.

[26] T. Suzuki, S. Hayashi, Y. Miki, et al., “Peroxisome proliferator-activated receptor γ in human breast carcinoma: a modulator of estrogenic actions,” Endocrine-Related Cancer, vol. 13, no. 1, pp. 233–250, 2006.

[27] C. Qin, R. Burghardt, R. Smith, M. Wormke, J. Stewart, and S. Safe, “Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells,” Cancer Research, vol. 63, no. 5, pp. 958–964, 2003.

[28] S. B. Nuñez, J. A. Medin, O. Braissant, et al., “Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor,” Molecular and Cellular Endocrinology, vol. 127, no. 1, pp. 27–40, 1997.

[29] C. H. Hurst and D. J. Waxman, “Activation of PPARα and PPARγ by environmental phthalate monoesters,” Toxicological Sciences, vol. 74, no. 2, pp. 297–308, 2003.

[30] M. T. Bility, J. T. Thompson, R. H. McKee, et al., “Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters,” Toxicological Sciences, vol. 82, no. 1, pp. 170–182, 2004.

[31] J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002.

[32] M. Gurnell, “Peroxisome proliferator-activated receptor γ and the regulation of adipocyte function: lessons from human genetic studies,” Best Practice & Research Clinical Endocrinology and Metabolism, vol. 19, no. 4, pp. 501–523, 2005.

[33] J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliwer, “An anti-diabetic thiazolidinediones is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.

[34] Y. Barak and S. Kim, “Genetic manipulations of PPARs: effects on obesity and metabolic disease,” PPAR Research, vol. 2007, Article ID 12781, 12 pages, 2007.

[35] S. Yu, K. Matsusue, P. Kashireddy, et al., “Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression,” The Journal of Biological Chemistry, vol. 278, no. 1, pp. 498–505, 2003.

[36] J. Vandesompele, K. De Preter, F. Pattyn, et al., “Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes,” Genome Biology, vol. 3, no. 7, pp. 1–12, 2002.

[37] J. S. Yuan, A. Reed, F. Chen, and C. N. Stewart Jr., “Statistical analysis of real-time PCR data,” BMC Bioinformatics, vol. 7, article 85, pp. 1–12, 2006.

[38] X. Wang and M. W. Kilgore, “Signal crosstalk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma in MDA-MB-23 1 and MCF7 breast cancer cells,” Molecular and Cellular Endocrinology, vol. 194, no. 1–2, pp. 123–133, 2002.

[39] D. Bonofiglio, S. Gabriele, S. Aquila, et al., “Estrogen receptor α binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer cells,” Clinical Cancer Research, vol. 11, no. 17, pp. 6139–6147, 2005.

[40] H.-J. Kim, J.-Y. Kim, Z. Meng, et al., “15-deoxy-D12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-α via covalent modification of DNA-binding domain,” Cancer Research, vol. 67, no. 6, pp. 2595–2602, 2007.

[41] F. Grün and B. Blumberg, “Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis,” Reviews in Endocrine & Metabolic Disorders, vol. 8, no. 2, pp. 161–171, 2007.

[42] R.R. Newbold, E. E. Padilla-Banks, R. J. Snyder, and W. N. Jefferson, “Developmental exposure to estrogenic compounds and obesity,” Birth Defects Research Part A Clinical and Molecular Teratology, vol. 73, pp. 478–480, 2005.

[43] R. R. Newbold, E. Padilla-Banks, R. J. Snyder, T. M. Phillips, and W. N. Jefferson, “Developmental exposure to endocrine
disruptors and the obesity epidemic,” *Reproductive Toxicology*, vol. 23, no. 3, pp. 290–296, 2007.

[44] H. Keller, F. Givel, M. Perroud, and W. Wahli, “Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements,” *Molecular Endocrinology*, vol. 9, no. 7, pp. 794–804, 1995.

[45] H. Ma, H. W. Sprecher, and P. E. Kolattukudy, “Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARγ-expressing tissue,” *The Journal of Biological Chemistry*, vol. 273, no. 46, pp. 30131–30138, 1998.

[46] H. Ma, Q. T. Tam, and P. E. Kolattukudy, “Peroxisome proliferator-activated receptor γ1 (PPAR-γ1) as a major PPAR in a tissue in which estrogen induces peroxisome proliferation,” *FEBS Letters*, vol. 434, no. 3, pp. 394–400, 1998.

[47] S. A. Kliewer, S. S. Sundseth, S. A. Jones, et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 9, pp. 4318–4323, 1997.

[48] B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12,14-prostaglandin J1 is a ligand for the adipocyte determination factor PPARγ,” *Cell*, vol. 83, no. 5, pp. 803–812, 1995.

[49] M. J. Dunn and V. L. Hood, “Prostaglandins and the kidney,” *American Journal of Physiology*, vol. 2, no. 3, pp. 169–184, 1977.

[50] J. P. Berger, T. E. Akiyama, and P. T. Meinke, “PPARs: therapeutic targets for metabolic disease,” *Trends in Pharmacological Sciences*, vol. 26, no. 5, pp. 244–251, 2005.

[51] G. Chinetti, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” *Inflammation Research*, vol. 49, no. 10, pp. 497–505, 2000.

[52] L. Gelman, J.-C. Fruchart, and J. Auwerx, “An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer,” *Cellular and Molecular Life Sciences*, vol. 55, no. 6-7, pp. 932–943, 1999.

[53] C.-H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” *Science*, vol. 302, no. 5644, pp. 453–457, 2003.

[54] C. M. Komar, “Peroxisome proliferator-activated receptors (PPARs) and ovarian function:implications for regulating steroidogenesis, differentiation, and tissue remodeling,” *Reproductive Biology and Endocrinology*, vol. 3, article 41, pp. 1–14, 2005.

[55] J. C. Corton and P. J. Lapinskas, “Peroxisome proliferator-activated receptors: mediators of phthalate ester-induced effects in the male reproductive tract?” *Toxicological Sciences*, vol. 83, no. 1, pp. 4–17, 2005.
Submit your manuscripts at
http://www.hindawi.com